First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Yap, T.; Vieito, M.; Baldini, C.; Sepúlveda-Sánchez, J.; Kondo, S.; Simonelli, M.; Cosman, R.; van der Westhuizen, A.; Atkinson, V.; Carpentier, A.; Löhr, M.; Redman, R.; Mason, W.; Cervantes, A.; Le Rhun, E.; Ochsenreither, S.; Warren, Louise; Zhao, Yumin; Callies, S.; T. Estrem, S.; Man, M.; Gandhi, L.; Avşar, Emin; Melisi, D.

doi:10.1158/1078-0432.CCR-21-1504

Public

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Shared by NobleBlocks on Sep 21, 2021 • 12:00 AM UTC

Authors:

T. Yap

M. Vieito

C. Baldini

Abstract

Purpose: A novel, selective, next-generation transforming growth factor beta (TGFβ) receptor type-1 small molecule inhibitor, LY3200882, demonstrated promising preclinical data. This first-in-human trial evaluated safety, tolerability, recommended phase II dose (RP2D), pharmacokinetics, pharmacodyna...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!